HBK Investments L P bought a new position in AstraZeneca plc (NYSE:AZN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 23,400 shares of the company’s stock, valued at approximately $812,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. acquired a new stake in AstraZeneca in the 4th quarter worth approximately $101,000. Valeo Financial Advisors LLC acquired a new stake in AstraZeneca in the 3rd quarter worth approximately $133,000. Delpha Capital Management LLC acquired a new stake in AstraZeneca in the 4th quarter worth approximately $152,000. Calton & Associates Inc. acquired a new stake in AstraZeneca in the 4th quarter worth approximately $181,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in AstraZeneca in the 3rd quarter worth approximately $184,000. Hedge funds and other institutional investors own 15.13% of the company’s stock.
AZN stock opened at $34.17 on Friday. AstraZeneca plc has a 1-year low of $28.43 and a 1-year high of $36.70. The company has a market capitalization of $87,308.93, a P/E ratio of 14.42, a PEG ratio of 1.79 and a beta of 0.71. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93.
The firm also recently declared a semiannual dividend, which was paid on Monday, March 19th. Stockholders of record on Friday, February 16th were issued a dividend of $0.95 per share. The ex-dividend date was Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio (DPR) is presently 57.81%.
Several equities research analysts recently weighed in on the company. BMO Capital Markets restated a “buy” rating and issued a $38.00 target price on shares of AstraZeneca in a report on Friday, January 26th. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. ValuEngine upgraded AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 3rd. Leerink Swann restated a “market perform” rating and issued a $36.00 target price (up from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Finally, Sanford C. Bernstein boosted their target price on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $36.32.
WARNING: “HBK Investments L P Buys New Holdings in AstraZeneca plc (AZN)” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3295600/hbk-investments-l-p-buys-new-holdings-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.